Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a ...

The drug is also being studied in other immune ... Upadacitinib will face two main JAK inhibitor competitors – Eli Lilly’s Olumiant and Pfizer’s Xeljanz. Despite excitement surrounding ...

Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...

In its pursuit of a cancer drug for pancreatic cancer and possibly ovarian cancer, Amplia has history on its side.

For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat ...

Explore Belatacept's role in organ transplant care, and market insights on immunosuppressants, JAK inhibitors, and dd-cfDNA ...

There’s a balance required to manage both the symptoms of myelofibrosis through treatment and the side effects caused by the ...

For those whose disease does not respond to these therapies, a class of drugs called Janus kinase (JAK) inhibitors offer another treatment option. BMS’ Sotyktu could bring patients another ...